CO2021010326A2 - Composición líquida de clotrimazol envasada de dosis única - Google Patents

Composición líquida de clotrimazol envasada de dosis única

Info

Publication number
CO2021010326A2
CO2021010326A2 CONC2021/0010326A CO2021010326A CO2021010326A2 CO 2021010326 A2 CO2021010326 A2 CO 2021010326A2 CO 2021010326 A CO2021010326 A CO 2021010326A CO 2021010326 A2 CO2021010326 A2 CO 2021010326A2
Authority
CO
Colombia
Prior art keywords
composition
liquid composition
clotrimazole
pharmaceutically
container
Prior art date
Application number
CONC2021/0010326A
Other languages
English (en)
Inventor
Mendoza Maria Mar Terraz
Aquilué Javier Sanagustín
Molina Adolfo Téllez
Gañán María Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of CO2021010326A2 publication Critical patent/CO2021010326A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una unidad de envasado de dosis única que es un envase de soplado, llenado y sellado (blow-fill-seal, BFS) que comprende una composición líquida estéril farmacéutica o veterinaria que es una solución, donde a) la composición comprende una cantidad terapéuticamente efectiva de clotrimazol o una sal farmacéutica o veterinariamente aceptable del mismo, junto con uno o más excipientes o vehículos farmacéutica o veterinariamente aceptables, y b) el envase tiene un volumen desde 0,05 hasta 8 mL, con la condición de que el contenido de agua de la composición es igual o inferior al 4% en peso con respecto al peso total de la composición. También se refiere a un envase secundario que comprende una o más unidades de envasado de dosis única.
CONC2021/0010326A 2019-02-19 2021-08-05 Composición líquida de clotrimazol envasada de dosis única CO2021010326A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382120 2019-02-19
PCT/EP2020/054250 WO2020169611A1 (en) 2019-02-19 2020-02-18 Single-dose packaged clotrimazole liquid composition

Publications (1)

Publication Number Publication Date
CO2021010326A2 true CO2021010326A2 (es) 2021-08-19

Family

ID=65766941

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0010326A CO2021010326A2 (es) 2019-02-19 2021-08-05 Composición líquida de clotrimazol envasada de dosis única

Country Status (22)

Country Link
US (1) US20220133695A1 (es)
EP (1) EP3927310B1 (es)
JP (1) JP7514844B2 (es)
KR (1) KR20210131313A (es)
CN (1) CN113423382A (es)
AU (1) AU2020225663B2 (es)
CA (1) CA3127151A1 (es)
CL (1) CL2021001882A1 (es)
CO (1) CO2021010326A2 (es)
CR (1) CR20210473A (es)
DO (1) DOP2021000169A (es)
IL (1) IL284858A (es)
MA (1) MA55007A (es)
MX (1) MX2021008803A (es)
PE (1) PE20211892A1 (es)
PL (1) PL3927310T3 (es)
RS (1) RS65657B1 (es)
SA (1) SA521422538B1 (es)
SG (1) SG11202107773RA (es)
TW (1) TWI834808B (es)
WO (1) WO2020169611A1 (es)
ZA (1) ZA202105236B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012967A (es) 2016-04-25 2019-03-06 Koska Family Ltd Sistema de suministro medico.
US20240091268A1 (en) * 2022-09-07 2024-03-21 Combangio, Inc. Preparation and purification methods for mesenchymal stem cell derived secretome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563365A1 (en) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
EP2094264A1 (en) * 2006-11-16 2009-09-02 E-Therapeutics Limited Clotrimazol for treating staphylococcal infections
GB0700380D0 (en) 2007-01-09 2007-02-14 Breath Ltd Storage Of Ampoules
DE102007056462B4 (de) * 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
WO2012083138A2 (en) * 2010-12-16 2012-06-21 Board Of Regents, The University Of Texas System Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
US8933112B2 (en) * 2012-06-15 2015-01-13 Memphaceuticals, LLC Topical liquid to ameliorate pain and promote healing of burn-injured skin
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations

Also Published As

Publication number Publication date
DOP2021000169A (es) 2021-09-30
PE20211892A1 (es) 2021-09-22
EP3927310C0 (en) 2024-04-10
ZA202105236B (en) 2023-10-25
AU2020225663A1 (en) 2021-08-12
TWI834808B (zh) 2024-03-11
CR20210473A (es) 2021-10-08
CA3127151A1 (en) 2020-08-27
JP7514844B2 (ja) 2024-07-11
TW202045161A (zh) 2020-12-16
AU2020225663B2 (en) 2024-03-14
WO2020169611A1 (en) 2020-08-27
US20220133695A1 (en) 2022-05-05
CL2021001882A1 (es) 2022-02-11
MX2021008803A (es) 2021-11-12
PL3927310T3 (pl) 2024-08-05
IL284858A (en) 2021-08-31
JP2022520714A (ja) 2022-04-01
KR20210131313A (ko) 2021-11-02
MA55007A (fr) 2021-12-29
RS65657B1 (sr) 2024-07-31
SG11202107773RA (en) 2021-08-30
EP3927310A1 (en) 2021-12-29
SA521422538B1 (ar) 2024-03-28
EP3927310B1 (en) 2024-04-10
CN113423382A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
CO2021010326A2 (es) Composición líquida de clotrimazol envasada de dosis única
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
SV2017005596A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
UY32760A (es) Composición farmacéutica para un inhibidor de proteasa del virus de la hepatitis c
DOP2017000293A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
JP2022062078A5 (es)
CL2021000290A1 (es) Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente
CO2019009613A2 (es) Procedimiento para el llenado gravimétrico en condiciones estériles de sólidos en un contenedor farmacéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
PE20021075A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
JP6741286B2 (ja) 包装されたアセトアミノフェン注射液製剤の製造方法
AR112265A1 (es) Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatos
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
RU2013124416A (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
MX2023006369A (es) Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona.
JP2006025953A (ja) ホリナート類水溶液充填プレフィルドシリンジ包装体
PE20141817A1 (es) Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv
CL2023003478A1 (es) Recipiente para medicamentos, comprende composición farmacéutica líquida 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
ECSDI23001193S (es) Envase de embalaje para medicamento
ECSDI23001190S (es) Envase de embalaje para medicamento
Petrov Tafluprost--a novel prostaglandin F2alpha analogue
RU2012108883A (ru) Терапевтическая комбинация, включающая легочный сурфактант и антиоксидантные ферменты
UY39658A (es) Formulación y métodos de gliburida de baja absorción
RU2020125724A (ru) Глазные капли в форме раствора, содержащего производное бензопирана или его фармацевтически приемлемую соль